Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 219

1.

Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial.

Stone GW, McCullough PA, Tumlin JA, Lepor NE, Madyoon H, Murray P, Wang A, Chu AA, Schaer GL, Stevens M, Wilensky RL, O'Neill WW; CONTRAST Investigators.

JAMA. 2003 Nov 5;290(17):2284-91.

PMID:
14600187
2.
3.

Preventing contrast-induced nephropathy with fenoldopam.

Hunter DW, Chamsuddin A, Bjarnason H, Kowalik K.

Tech Vasc Interv Radiol. 2001 Mar;4(1):53-6.

PMID:
11981789
4.

Fenoldopam mesylate in early acute tubular necrosis: a randomized, double-blind, placebo-controlled clinical trial.

Tumlin JA, Finkel KW, Murray PT, Samuels J, Cotsonis G, Shaw AD.

Am J Kidney Dis. 2005 Jul;46(1):26-34.

PMID:
15983954
5.

Design and rationale of CONTRAST--a prospective, randomized, placebo-controlled trial of fenoldopam mesylate for the prevention of radiocontrast nephropathy.

Stone GW, Tumlin JA, Madyoon H, Lepor NE, McCullough PA, Mathur VS, Murray PT, O'Neill WW.

Rev Cardiovasc Med. 2001;2 Suppl 1:S31-6.

PMID:
12439366
6.

Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy.

Allaqaband S, Tumuluri R, Malik AM, Gupta A, Volkert P, Shalev Y, Bajwa TK.

Catheter Cardiovasc Interv. 2002 Nov;57(3):279-83.

PMID:
12410497
7.

Using a dopamine type 1A receptor agonist in high-risk patients to ameliorate contrast-associated nephropathy.

Chamsuddin AA, Kowalik KJ, Bjarnason H, Dietz CA, Rosenberg MS, Gomes MD, McDermott CM, Hunter DW.

AJR Am J Roentgenol. 2002 Sep;179(3):591-6. Erratum in: AJR Am J Roentgenol 2002 Dec;179(6):1645.

PMID:
12185025
8.

Effect of theophylline on contrast material-nephropathy in patients with chronic renal insufficiency: controlled, randomized, double-blinded study.

Huber W, Ilgmann K, Page M, Hennig M, Schweigart U, Jeschke B, Lutilsky L, Weiss W, Salmhofer H, Classen M.

Radiology. 2002 Jun;223(3):772-9.

PMID:
12034949
9.

A protocol for prevention of radiographic contrast nephropathy during percutaneous coronary intervention: effect of selective dopamine receptor agonist fenoldopam.

Kini AS, Mitre CA, Kim M, Kamran M, Reich D, Sharma SK.

Catheter Cardiovasc Interv. 2002 Feb;55(2):169-73.

PMID:
11835641
10.

Effect of fenoldopam on use of renal replacement therapy among patients with acute kidney injury after cardiac surgery: a randomized clinical trial.

Bove T, Zangrillo A, Guarracino F, Alvaro G, Persi B, Maglioni E, Galdieri N, Comis M, Caramelli F, Pasero DC, Pala G, Renzini M, Conte M, Paternoster G, Martinez B, Pinelli F, Frontini M, Zucchetti MC, Pappalardo F, Amantea B, Camata A, Pisano A, Verdecchia C, Dal Checco E, Cariello C, Faita L, Baldassarri R, Scandroglio AM, Saleh O, Lembo R, Calabrò MG, Bellomo R, Landoni G.

JAMA. 2014 Dec 3;312(21):2244-53. doi: 10.1001/jama.2014.13573.

PMID:
25265449
11.
12.

N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity.

Briguori C, Colombo A, Airoldi F, Violante A, Castelli A, Balestrieri P, Paolo Elia P, Golia B, Lepore S, Riviezzo G, Scarpato P, Librera M, Focaccio A, Ricciardelli B.

J Am Coll Cardiol. 2004 Aug 18;44(4):762-5.

13.

A comparison between fenoldopam and low-dose dopamine in early renal dysfunction of critically ill patients.

Brienza N, Malcangi V, Dalfino L, Trerotoli P, Guagliardi C, Bortone D, Faconda G, Ribezzi M, Ancona G, Bruno F, Fiore T.

Crit Care Med. 2006 Mar;34(3):707-14.

PMID:
16505657
14.

Prophylactic fenoldopam for renal protection in sepsis: a randomized, double-blind, placebo-controlled pilot trial.

Morelli A, Ricci Z, Bellomo R, Ronco C, Rocco M, Conti G, De Gaetano A, Picchini U, Orecchioni A, Portieri M, Coluzzi F, Porzi P, Serio P, Bruno A, Pietropaoli P.

Crit Care Med. 2005 Nov;33(11):2451-6.

PMID:
16276165
15.

Comparison of N-acetylcysteine and fenoldopam for preventing contrast-induced nephropathy (CAFCIN).

Ng TM, Shurmur SW, Silver M, Nissen LR, O'Leary EL, Rigmaiden RS, Cieciorka M, Porter LL, Ineck BA, Kline ME, Puumala SE.

Int J Cardiol. 2006 May 24;109(3):322-8. Epub 2005 Jul 22.

PMID:
16039733
16.

N-acetylcysteine and fenoldopam protect the renal function of patients with chronic renal insufficiency undergoing cardiac surgery.

Barr LF, Kolodner K.

Crit Care Med. 2008 May;36(5):1427-35. doi: 10.1097/CCM.0b013e31816f48ba.

PMID:
18434903
17.

Fenoldopam: renal and splanchnic effects in patients undergoing coronary artery bypass grafting.

Halpenny M, Lakshmi S, O'Donnell A, O'Callaghan-Enright S, Shorten GD.

Anaesthesia. 2001 Oct;56(10):953-60.

18.

Fenoldopam and renal function after partial nephrectomy in a solitary kidney: a randomized, blinded trial.

O'Hara JF Jr, Mahboobi R, Novak SM, Bonilla AM, Mascha EJ, Fergany AF, Campbell SC, Kaouk JH, Kaple KM, Gill IS, Ziegman SA, Sessler DI.

Urology. 2013 Feb;81(2):340-5. doi: 10.1016/j.urology.2012.09.041.

PMID:
23374797
19.

Effectiveness of theophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency.

Huber W, Schipek C, Ilgmann K, Page M, Hennig M, Wacker A, Schweigart U, Lutilsky L, Valina C, Seyfarth M, Schömig A, Classen M.

Am J Cardiol. 2003 May 15;91(10):1157-62.

PMID:
12745095
20.

Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography.

Oldemeyer JB, Biddle WP, Wurdeman RL, Mooss AN, Cichowski E, Hilleman DE.

Am Heart J. 2003 Dec;146(6):E23.

PMID:
14661012

Supplemental Content

Support Center